Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.

about

Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.

Item

http://www.wikidata.org/entity/Q39766258

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh

2011年學術文章

@zh-hant

name

Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.

@en

Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.

@nl

type

Item

label

Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.

@en

Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.

@nl

prefLabel

Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.

@en

Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy.

@nl

P1476

Update in Urothelial Carcinoma: Novel Agents and Targeted Therapy

@en

P2093

Christopher J Sweeney

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Guancial

http://www.w3.org/2001/XMLSchema#string

Jonathan E Rosenberg

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2010

Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.

Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium.

A phase I trial of BMS-247550 (NSC# 710428) and gemcitabine in patients with advanced solid tumors.

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

MDR1 and ERCC1 expression predict outcome of patients with locally advanced bladder cancer receiving adjuvant chemotherapy.

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract.

Platinum resistance: the role of DNA repair pathways.

P304

171-176

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P478

2011

http://www.w3.org/2001/XMLSchema#string

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26430392

http://www.w3.org/2001/XMLSchema#string

P932

4587660

http://www.w3.org/2001/XMLSchema#string